MABVAX THERAPEUTICS HOLDINGS, INC. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016	Q1 FY2016 As of Mar 31, 2016	Q4 FY2015 As of Dec 31, 2015	Q3 FY2015 As of Sep 30, 2015	Q2 FY2015 As of Jun 30, 2015	Q1 FY2015 As of Mar 31, 2015	Q3 FY2014 As of Sep 30, 2014	Q2 FY2014 As of Jun 30, 2014	Q1 FY2014 As of Mar 31, 2014	Q4 FY2013 As of Dec 31, 2013	Q3 FY2013 As of Sep 30, 2013
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Other receivables
Prepaids and other current assets
Receivable
Grants receivable
Prepaid expenses
Deferred financing costs
Other current assets
Total current assets

Restricted investments
Property and equipment, net
Goodwill
Other assets
Total assets

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued compensation
Accrued clinical operations and site costs
Accrued contingent lease termination fee
Related party liabilities
Accrued lease termination fee
License fee payable
Other accrued expenses
Warrant liability
Interest payable
Current portion of notes payable
Current portion of capital leases payable
Total current liabilities

Warrant liability
Non-current liabilities:
Long-term portion of notes payable, net
Non-current portion of notes payable, net
Non-current portion of capital lease payable
Other non-current liabilities
Total non-current liabilities
Total liabilities
MabVax Therapeutics Holdings Series B redeemable convertible preferred stock, 1,250,000 shares authorized, none and 1,250,000 issued and outstanding as of December 31, 2015 and 2014, respectively, with a liquidation preference of $2,627,123 as of December 31, 2014
Redeemable Convertible Preferred Stock
Total mabVax Therapeutics Holdings Series B redeemable convertible preferred stock, 1,250,000 shares authorized, none and 1,250,000 issued and outstanding as of December 31, 2015 and 2014, respectively, with a liquidation preference of $2,627,123 as of December 31, 2014

Total redeemable convertible preferred stock
Stockholders' Equity:
Common stock
Preferred stock
Series A-1 Convertible Preferred Stock
Series C Convertible Preferred Stock
Series A-1 Preferred Stock
Series C Preferred Stock
Series D Preferred Stock
Series E Preferred Stock
Series D Convertible Preferred Stock
Series E Convertible Preferred Stock
Series F Convertible Preferred Stock
Series G Convertible Preferred Stock
Series H Convertible Preferred Stock
Series I Convertible Preferred Stock
Series J Convertible Preferred Stock
Series K Convertible Preferred Stock
Series L Convertible Preferred Stock
Series M Convertible Preferred Stock
Series N Convertible Preferred Stock
Series O Convertible Preferred Stock

Common stock, $0.01 par value, 150,000,000 shares authorized, 9,254,582 and 6,862,928 shares issued and outstanding as of September 30, 2018 and December 31, 2017, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments